Literature DB >> 27126993

Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors.

Ya'an Kang1, David Roife2, Yeonju Lee3, Hailong Lv4, Rei Suzuki5, Jianhua Ling6, Mayrim V Rios Perez1, Xinqun Li1, BingBing Dai1, Michael Pratt1, Mark J Truty7, Deyali Chatterjee8, Huamin Wang9, Ryan M Thomas10, Yu Wang11, Eugene J Koay3, Paul J Chiao6, Matthew H Katz1, Jason B Fleming12.   

Abstract

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is lethal cancer whose primary tumor is characterized by dense composition of cancer cells, stromal cells, and extracellular matrix (ECM) composed largely of collagen. Within the PDAC tumor microenvironment, activated pancreatic stellate cells (PSC) are the dominant stromal cell type and responsible for collagen deposition. Lumican is a secreted proteoglycan that regulates collagen fibril assembly. We have previously identified that the presence of lumican in the ECM surrounding PDAC cells is associated with improved patient outcome after multimodal therapy and surgical removal of localized PDAC. EXPERIMENTAL
DESIGN: Lumican expression in PDAC from 27 patients was determined by IHC and quantitatively analyzed for colocalization with PSCs. In vitro studies examined the molecular mechanisms of lumican transcription and secretion from PSCs (HPSCs and HPaSteC), and cell adhesion and migration assays examined the effect of lumican on PSCs in a collagen-rich environment.
RESULTS: Here we identify PSCs as a significant source of extracellular lumican production through quantitative IHC analysis. We demonstrate that the cytokine, TGF-β, negatively regulates lumican gene transcription within HPSCs through its canonical signaling pathway and binding of SMAD4 to novel SBEs identified within the promoter region. In addition, we found that the ability of HPSCs to produce and secrete extracellular lumican significantly enhances HPSCs adhesion and mobility on collagen.
CONCLUSIONS: Our results demonstrate that activated pancreatic stellate cells within PDAC secrete lumican under the negative control of TGF-β; once secreted, the extracellular lumican enhances stellate cell adhesion and mobility in a collagen-rich environment. Clin Cancer Res; 22(19); 4934-46. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27126993      PMCID: PMC5127652          DOI: 10.1158/1078-0432.CCR-15-2780

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  48 in total

1.  Effects of the extracellular matrix on lumican expression in rat aortic smooth muscle cells in vitro.

Authors:  H Qin; T Ishiwata; G Asano
Journal:  J Pathol       Date:  2001-12       Impact factor: 7.996

Review 2.  The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth.

Authors:  R V Iozzo
Journal:  Crit Rev Biochem Mol Biol       Date:  1997       Impact factor: 8.250

3.  Multispectral imaging and pathology: seeing and doing more.

Authors:  Richard M Levenson; Alessandro Fornari; Massimo Loda
Journal:  Expert Opin Med Diagn       Date:  2008-09

4.  Fibromodulin and lumican bind to the same region on collagen type I fibrils.

Authors:  L Svensson; I Närlid; A Oldberg
Journal:  FEBS Lett       Date:  2000-03-24       Impact factor: 4.124

5.  Pancreatic tumor cells influence the composition of the extracellular matrix.

Authors:  Jörg Köninger; Thomas Giese; Fabio F di Mola; Moritz N Wente; Irene Esposito; Max G Bachem; Nathalia A Giese; Markus W Büchler; Helmut Friess
Journal:  Biochem Biophys Res Commun       Date:  2004-09-24       Impact factor: 3.575

6.  Pancreatic cancer stroma: friend or foe?

Authors:  Jesse Gore; Murray Korc
Journal:  Cancer Cell       Date:  2014-06-16       Impact factor: 31.743

7.  Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells.

Authors:  Hongmei Wang; Venugopal Radjendirane; Kishore K Wary; Subhas Chakrabarty
Journal:  Oncogene       Date:  2004-07-15       Impact factor: 9.867

8.  Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells.

Authors:  Dragana Nikitovic; Aikaterini Berdiaki; Alexandros Zafiropoulos; Pavlos Katonis; Aristidis Tsatsakis; Nikos K Karamanos; George N Tzanakakis
Journal:  FEBS J       Date:  2007-12-17       Impact factor: 5.542

9.  Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Yoko Matsuda; Tetsushi Yamamoto; Mitsuhiro Kudo; Kiyoko Kawahara; Masashi Kawamoto; Yuki Nakajima; Kiyoshi Koizumi; Nando Nakazawa; Toshiyuki Ishiwata; Zenya Naito
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

10.  SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7.

Authors:  Gareth J Inman; Francisco J Nicolás; James F Callahan; John D Harling; Laramie M Gaster; Alastair D Reith; Nicholas J Laping; Caroline S Hill
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  12 in total

1.  Prolonged exposure to extracellular lumican restrains pancreatic adenocarcinoma growth.

Authors:  X Li; Y Kang; D Roife; Y Lee; M Pratt; M R Perez; B Dai; E J Koay; J B Fleming
Journal:  Oncogene       Date:  2017-05-22       Impact factor: 9.867

2.  Preclinical Evaluation of Sequential Combination of Oncolytic Adenovirus Delta-24-RGD and Phosphatidylserine-Targeting Antibody in Pancreatic Ductal Adenocarcinoma.

Authors:  Bingbing Dai; David Roife; Ya'an Kang; Joy Gumin; Mayrim V Rios Perez; Xinqun Li; Michael Pratt; Rolf A Brekken; Juan Fueyo-Margareto; Frederick F Lang; Jason B Fleming
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

3.  Characterization of the Immune Cell Infiltration Profile in Pancreatic Carcinoma to Aid in Immunotherapy.

Authors:  Fei Kuang; Juan Du; Mengjia Zhou; Fangyi Peng; Yu Gan; Cheng Fang; Xiaoli Yang; Bo Li; Song Su
Journal:  Front Oncol       Date:  2021-05-13       Impact factor: 6.244

Review 4.  Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma.

Authors:  Qi Wu; Ying Tian; Jingqiu Zhang; Hongpeng Zhang; Fengming Gu; Yongdie Lu; Shengnan Zou; Yuji Chen; Pengxiang Sun; Mengyue Xu; Xiaoming Sun; Chao Xia; Hao Chi; A Ying Zhu; Dong Tang; Daorong Wang
Journal:  Oncotarget       Date:  2017-10-19

Review 5.  Chemotherapy and tumor microenvironment of pancreatic cancer.

Authors:  Qiaofei Liu; Quan Liao; Yupei Zhao
Journal:  Cancer Cell Int       Date:  2017-07-05       Impact factor: 5.722

6.  Lumican expression in gastric cancer and its association with biological behavior and prognosis.

Authors:  Li Chen; Yuxin Zhang; Yanjiao Zuo; Fei Ma; Hongjiang Song
Journal:  Oncol Lett       Date:  2017-08-28       Impact factor: 2.967

7.  Hypoxia-Induced Autophagy Degrades Stromal Lumican into Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma: A Mini-Review.

Authors:  Bhaswati Sarcar; Xinqun Li; Jason B Fleming
Journal:  J Cancer Treatment Diagn       Date:  2019-02-22

8.  Identification of key regulators of pancreatic ductal adenocarcinoma using bioinformatics analysis of microarray data.

Authors:  Nan Li; Xin Zhao; Shengyi You
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

Review 9.  The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.

Authors:  Yaojie Fu; Shanshan Liu; Shan Zeng; Hong Shen
Journal:  Mol Cancer       Date:  2018-02-19       Impact factor: 27.401

10.  Disparate Remodeling of the Extracellular Matrix and Proteoglycans in Failing Pediatric Versus Adult Hearts.

Authors:  Sayantan Jana; Hao Zhang; Gary D Lopaschuk; Darren H Freed; Consolato Sergi; Paul F Kantor; Gavin Y Oudit; Zamaneh Kassiri
Journal:  J Am Heart Assoc       Date:  2018-10-02       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.